Table 5.
Characteristics | Positive, n (%) | Negative, n (%) | Crude odds ratio | 95% CI |
---|---|---|---|---|
Number of PET/CT scans | 38 | 17 | ||
Initial treatment RP | 15 (39.5) | 15 (88.2) | 1.0 | Ref. |
Initial treatment EBRT | 22 (57.9) | 2 (11.8) | 11.0 | 2.2–55.3 |
Trigger PSA <2 ng/mL | 3 (7.9) | 9 (52.9) | 1.0 | Ref. |
Trigger PSA ≥2 ng/mL | 34 (89.5) | 8 (47.1) | 12.8 | 2.8–58.1 |
PSAV <1 ng/mL/year | 4 (10.5) | 11 (64.7) | 1.0 | Ref. |
PSAV ≥1 but <5 ng/mL/year | 14 (36.8) | 5 (29.4) | 7.7 | 1.7–35.7 |
PSAV ≥5 ng/mL/year | 16 (42.1) | 1 (5.9) | 44.0 | 4.3–448.3 |
PET/CT: positron emission tomography-computed tomography; CI: confidence interval; EBRT: external beam radiation therapy; PSA: prostate-specific antigen; PSADT: prostate-specific antigen doubling time; PSAV: prostate-specific antigen velocity; RP: radical prostatectomy; Ref.: reference; SD: standard deviation.